trending Market Intelligence /marketintelligence/en/news-insights/trending/mi3akatailbazmmjvaozqa2 content esgSubNav
In This List

Akers Biosciences gets delinquency notice from Nasdaq

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Akers Biosciences gets delinquency notice from Nasdaq

Akers Biosciences Inc. said it received a delinquency notice from the Nasdaq Stock Market for failure to timely file its Form 10-Q for the quarter ended March 31.

The New Jersey-based company has 60 calendar days from receipt of the notice to submit a plan to regain compliance. If the plan is accepted, the company may be granted an extension of up to 180 calendar days from the filing due date, or until Nov. 19, to regain complaisance.

The notice will have no immediate effect on the company's listing on Nasdaq.

Akers Biosciences makes and sells rapid screening and testing products for the healthcare industry.